Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: It has been reported that 50% of patients with atrophic body gastritis have positive Helicobacter pylori antibody titres only. In atrophic body gastritis, a decrease in H. pylori antibodies after eradication treatment has been reported, suggesting that serology may indicate an active H. pylori infection. Aim: To investigate the time course of H. pylori antibodies and gastric inflammation after eradication treatment in patients with atrophic body gastritis, and to determine whether serology alone can be considered as a valid tool to assess the efficacy of eradication treatment in patients with atrophic body gastritis. Methods: Twenty‐seven patients with atrophic body gastritis (12 serologically H. pylori‐positive only, ABG‐S+; 15 H. pylori‐positive at histology and serology, ABG‐H+) were included in the treatment group, and 17 patients (all ABG‐S+) in the no treatment group. All patients had gastroscopy plus biopsies evaluated according to the updated Sydney system and H. pylori immunoglobulin G determination: in the treatment group, at baseline and 6 and 24 months after eradication (bismuth‐based triple regimens); in the no treatment group, at baseline and after 3 years. Results: In the treatment group, in ABG‐S+ patients, H. pylori antibodies decreased significantly 6 months after treatment [37.5 U/mL (16–100 U/mL) vs. 15 U/mL (0–100 U/mL), P < 0.01], but 2 years after treatment no further decrease occurred. In addition, in ABG‐H+ patients, a significant decrease in H. pylori antibodies occurred 6 months after treatment [45 U/mL (12.5–100 U/mL) vs. 31 U/mL (0–65 U/mL), P < 0.01], but a further decrease was also observed 2 years after treatment [20 U/mL (0–56 U/mL), P < 0.01]. In ABG‐S+ patients, no correlation was observed between the H. pylori antibodies and gastric inflammation score, whereas, in the ABG‐H+ group, this correlation was extremely significant (r=0.5991, P < 0.0001). In the no treatment group, at follow‐up, a significant decrease in H. pylori antibodies was observed [26 U/mL (15–100 U/mL) vs. 22 U/mL (0–53 U/mL), P < 0.05], but the gastric body inflammation remained unchanged. Conclusions: This study shows that, in ABG‐S+ patients after eradication treatment, serology does not keep in step with gastric inflammation. This suggests that, in patients with atrophic body gastritis, serology alone may not be valid for the assessment of the efficacy of eradication treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two‐thirds of Atrophic Body Gastritis Patients Have Evidence of Helicobacter pylori Infection
Annibale, B., Negrini, R., Caruana, P., Lahner, E., Grossi, C., Bordi, C., & Fave, G. D. (2001) · Helicobacter · doi:10.1046/j.1083-4389.2001.00032.x · Cited by 107
Self-citationAtrophic Body Gastritis: Distinct Features Associated with Helicobacter pylori Infection
Annibale, B., Marignani, M., Azzoni, C., D’ambra, G., Caruana, P., D’adda, T., Fave, G. D., & Bordi, C. (1997) · Helicobacter · doi:10.1111/j.1523-5378.1997.tb00060.x · Cited by 104
Self-citation
Cited by
Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate
Merola, E., Sbrozzi-Vanni, A., Panzuto, F., D’Ambra, G., Di Giulio, E., Pilozzi, E., Capurso, G., Lahner, E., Bordi, C., Annibale, B., et al. (2012) · Neuroendocrinology · doi:10.1159/000329043 · Cited by 132
Self-citationRisk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis
VANNELLA, L., LAHNER, E., OSBORN, J., BORDI, C., MIGLIONE, M., DELLE FAVE, G., & ANNIBALE, B. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04268.x · Cited by 110
Self-citationVannella, L., Sbrozzi-Vanni, A., Lahner, E., Bordi, C., Pilozzi, E., Corleto, V. D., Osborn, J. F., Delle Fave, G., & Annibale, B. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04659.x · Cited by 109
Self-citationLahner, E., Esposito, G., Pilozzi, E., Purchiaroni, F., Corleto, V. D., Di Giulio, E., & Annibale, B. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1010570 · Cited by 97
“pylori IgG was the criterion for the successful cure of infection [37].”
BackgroundSelf-citationReversal of atrophic body gastritis after H. pylori eradication at long-term follow-up
Vannella, L., Lahner, E., Bordi, C., Pilozzi, E., Di Giulio, E., Corleto, V. D., Osborn, J., Delle Fave, G., & Annibale, B. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.012 · Cited by 56
Self-citation
Metadata
- Authors
- Lahner, E., Bordi, C., Di Giulio, E., Caruana, P., D'Ambra, G., Milione, M., Grossi, C., Delle Fave, G., & Annibale, B.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2002-03
- Volume
- 16
- Issue
- 3
- Pages
- 507-514
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2047381680
- Cited by
- 37
- References
- 2
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. https://app.cochat.ai/papers/10.1046/j.1365-2036.2002.01213.x
- The paper
- Lahner, E., Bordi, C., Di Giulio, E., Caruana, P., D'Ambra, G., Milione, M., Grossi, C., Delle Fave, G., & Annibale, B. (2002). Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2002.01213.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.